[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anorexia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anorexia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,82,107,134,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100433358","impact-of-auditory-stimulation-in-eating-pleasure-edere-2021-100433358",false,"NCT04923087","Impact of Auditory Stimulation in Eating Pleasure (EDERE 2021)","Impact of Auditory Stimulation in Eating Pleasure : Multicentric Study With Biscuits With Crunchy Texture vs Soft Texture in 100 Seniors Affected or at Risk of Presbyacusis","EDERE 2021","Inclusion Criteria:\n\nSubjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents.\n\nExclusion Criteria:\n\nrisk of false route when eating cookies, allergy to an ingredient in cookies",true,"ALL","65 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","Background. Decreased taste and smell contribute to loss of appetite (anorexia), and the resulting protein-energy malnutrition increases the frailty of the elderly. The risk of falls, disability, infections and depression often requires them to be institutionalized. Elderly, undernourished and toothless patients often complain about the monotony of a soft, mixed-texture diet. In a previous study, some participants highlighted the pleasure of crunching cookies that have a solid texture that can be eaten in any dental condition. However, the age-related decrease in hearing (presbyacusis) is frequent and progressive from the age of 60. The hypothesis of this work is that older patients may perceive a crunchy food crunching in their mouth, despite presbycusis. If the hypothesis is verified, this would make geriatric caregivers aware of the possibility of diversifying the texture of food, in order to stimulate the pleasure of eating and increase the dietary intake in this population of patients who are often undernourished, dysphagic, edentulous and hearing impaired. The originality of this study is to share the expertise of geriatricians and specialists in mastication\u002Fswallowing (dental surgeon, speech-language pathologist), hearing (ENT doctor, hearing care professional) and nutrition (dietician).\n\nType of study. Type of study MR-004 \"Research not involving the human person\". Protocol. Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements: a soft filled cookie (Nutra Cake™, Délical, France) and a crunchy cookie of the Breton type (Protibis™, Solidages, France). Blind study impossible: each subject will eat a cookie then the other in a random order and will be his own control. The tests will be performed without the possible hearing aids, but with or without the dentures according to the patient's preference. Indeed, some patients have dental prostheses that are no longer suitable for chewing, and that they wear only for aesthetics. Objective. Validate the evaluation criteria \"Do you hear the biscuit crunch?\" and \"Is it a pleasure?\" If so, encourage diversification with crunchy foods with a suitable texture, as well as dental and prosthetic rehabilitation of dependent elderly people.",[26,27,28,29,30],"Frailty","Malnutrition","Anorexia","Presbycusis","Edentulism Nos","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-29","ACTUAL",{"date":37,"type":35},"2021-06-01",{"date":39,"type":22},"2027-06-25",{"name":41,"class":42},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100561684","fecal-microbiota-transplant-for-anorexia-nervosa-100561684","NCT06593366","Fecal Microbiota Transplant for Anorexia Nervosa","A Pilot Feasibility Randomized Controlled Trial of Fecal Microbiota Transplant for Adolescent Anorexia Nervosa","FMT-AN","Inclusion Criteria: All study subjects will have been diagnosed with AN (restricting type or binge eating\u002Fpurging type) by the primary physician on the ED team, as per standard approach. Study participants will:\n\n* Be 12-17 years-old at time of recruitment\n* Have capacity to consent\n* Be assigned female sex at birth (may be gender diverse)\n* Be active patients in the pediatric ED program at MCH\n* Have a weight that is \\\u003C85% of the Treatment Goal Weight, as determined by the treating physician\n\nExclusion Criteria: Potential study subjects will be excluded due to the following reasons:\n\n* Exposure to antibiotics within two weeks of study randomization\n* Initiation of new probiotics \u002F oral nutritional supplements within two weeks of randomization\n* Active pregnancy\n* Active psychosis or suicidal ideation\n* Other comorbidities that may affect weight or the gut microbiome including celiac disease, inflammatory bowel disease (or other conditions as determined by the study team)","FEMALE","12 Years","17 Years",{"count":56,"type":22},20,"INTERVENTIONAL",[59],"NA","The purpose of this pilot randomized-controlled trial is to determine whether Fecal Microbiota Transplant (FMT) treatment demonstrates feasibility, acceptability, and prelinary effectiveness among patients with anorexia nervosa (AN). Specifically, the investigators aim to compare changes in weight, gut microbiome, urine, blood biomarkers and mood symptoms between participants receiving the FMT intervention and placebo.",[62,63,64,65,28],"Anorexia Nervosa Restricting Type","Anorexia Nervosa","Anorexia in Adolescence","Anorexia in Children",[67,68,69,70,71],"anorexia nervosa","fecal microbiota transplant","pilot study","randomized controlled trial","feasibility","NOT_YET_RECRUITING","2026-05-22",{"date":75,"type":35},"2026-05-27",{"date":77,"type":22},"2026-06-01",{"date":79,"type":22},"2027-06-01",{"name":81,"class":42},"Hamilton Health Sciences Corporation",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":57,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":43},"100636417","phase-2-nanocrystalline-megestrol-acetate-versus-placebo-for-anorexia-in-patients-with-unresectable-hepatocellular-carcinoma-receiving-tace-combined-with-targeted-and-immunotherapy-100636417","NCT07565415","Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy","A Multicenter, Randomized, Controlled Phase II Clinical Trial of Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy","Inclusion Criteria:\n\n* Patients with unresectable primary hepatocellular carcinoma (HCC) confirmed by imaging or histopathology\n* No previous receipt of immunotherapy and\u002For targeted drug therapy\n* Child-Pugh score ≤ 7\n* At least one measurable lesion per RECIST 1.1 criteria; lesions without prior radiotherapy, cryotherapy or other local treatment\n* Single intrahepatic lesion \\\u003C 10 cm, or fewer than 10 intrahepatic lesions with tumor burden \\\u003C 50%\n* Meet precachexia criteria: non-volitional weight loss ≤ 5% in 6 months, plus systemic inflammation (CRP \\> 5 mg\u002FL) or decreased appetite (FAACT-A\u002FCS-12 score ≤ 37 points)\n* Meet cachexia criteria: accompanied by decreased appetite or systemic inflammation, with either non-volitional weight loss \\> 5% in 6 months or BMI \\\u003C 18.5 kg\u002Fm² plus weight loss \\> 2%\n* Voluntarily participate and sign informed consent\n* Age ≥ 18 years, male or female\n* Able to swallow tablets normally\n* ECOG performance status 0 or 1\n* Life expectancy ≥ 12 weeks\n* Adequate major organ function without blood products or colony-stimulating factors within 14 days\n* Hematology: ANC ≥ 1.5×10⁹\u002FL, Hb ≥ 80 g\u002FL, PLT ≥ 50×10⁹\u002FL\n* Liver function: TBIL ≤ 1.5×ULN, AST\u002FALT ≤ 5.0×ULN, ALB ≥ 28 g\u002FL\n* Coagulation function: INR, PT or aPTT ≤ 1.5×ULN\n* Renal function: SCr ≤ 1.5×ULN or creatinine clearance ≥ 60 mL\u002Fmin\n* Urine protein ≤ 1+ or 24-hour urine protein \\\u003C 1.0 g\n* Cardiac function: LVEF ≥ 50%\n* Females of childbearing potential with negative pregnancy test within 3 days before first dosing\n* Fertile male and female patients agree to effective contraception from screening to 120 days after last study drug\n* HBV\u002FHCV infected patients receive stable antiviral therapy without drug interaction\n\nExclusion Criteria:\n\n* Active or untreated CNS metastases; inadequately controlled metastatic brain or leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Thromboembolic disease, ascites or lower limb edema within 6 months\n* History of other malignancies within 5 years before randomization, except curable low-risk tumors\n* Unresolved adverse toxicities from prior antitumor therapy not recovered to ≤ Grade 1 (CTCAE v5.0), excluding alopecia\n* Pregnant, breastfeeding females or those planning pregnancy during the study\n* Any unstable medical, psychiatric or social condition that may interfere with study participation\n* Positive HIV infection\n* Major surgery within 28 days prior to randomization\n* Severe cardiovascular disease, myocardial infarction, unstable arrhythmia, angina or cerebrovascular events\n* Severe systemic infection within 4 weeks before dosing or active infection requiring systemic anti-infective treatment\n* Impaired gastrointestinal absorption, long-term tube feeding, parenteral nutrition or eating disorders\n* Concomitant use of other appetite-enhancing or weight-stimulating agents\n* Cushing's syndrome, adrenal or pituitary insufficiency, poorly controlled diabetes\n* Uncontrolled hypertension despite oral antihypertensive treatment\n* Esophagogastric varices, severe ulcers, gastrointestinal bleeding, obstruction, perforation or fistula within 6 months\n* Known hypersensitivity to any component of the investigational product\n* Any other condition considered inappropriate for enrollment by the investigator.","18 Years",{"count":91,"type":22},88,[93],"PHASE2","Primary Objective: To evaluate the effect of nanocrystalline megestrol acetate versus placebo on body weight and appetite in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and immunotherapy.Secondary Objectives: To evaluate the effect of nanocrystalline megestrol acetate versus placebo on quality of life, inflammatory markers, nutritional indicators, and psychological stress in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and immunotherapy.Exploratory Objective: To explore the impact of nanocrystalline megestrol acetate versus placebo on survival benefit in patients with unresectable hepatocellular carcinoma receiving TACE combined with targeted and immunotherapy.",[96,97,28,27],"Hepatocellular Carcinoma (HCC)","Cachexia","2026-04-27",{"date":100,"type":35},"2026-05-04",{"date":102,"type":22},"2026-06-22",{"date":104,"type":22},"2027-09-01",{"name":106,"class":42},"Nanfang Hospital, Southern Medical University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":57,"phases":116,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100606710","the-effect-of-a-protective-oral-care-protocol-using-peppermint-oil-mouthwash-100606710","NCT07179094","The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash","The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash on Chemotherapy-Induced Nausea, Vomiting, and Loss of Appetite in Patients With Hematologic Malignancies","Inclusion Criteria:\n\n* Age 18 years or older\n* Clinical diagnosis of hematologic malignancy\n* History of at least one chemotherapy cycle\n* Scheduled to receive chemotherapy with high or moderate emetogenic risk agents\n* No oral mucositis before chemotherapy\n* No metastasis\n* Literate (able to read and write)\n* Volunteer to participate in the study\n\nExclusion Criteria:\n\n* Use of herbal remedies for nausea, vomiting, or anorexia\n* Concurrent radiotherapy with chemotherapy\n* Non-adherence to standard antiemetic therapy according to the chemotherapy preparation regimen and protocol (e.g., use of antiemetics other than granisetron or metoclopramide)\n* Known allergy to peppermint oil\n* Psychiatric disorders\n* Communication impairments (hearing or speech difficulties)\n* Altered level of consciousness\n* Endotracheal intubation\n* Requirement for oral care solutions other than the clinic's routine procedures (saline or sodium bicarbonate)\n* Chronic gastrointestinal diseases (gastritis, gastric\u002Fpeptic ulcer, ulcerative colitis, Crohn's disease, gastroesophageal reflux, irritable bowel syndrome, cirrhosis, or pancreatitis)\n* Migraine\n* Brain metastases\n* Hepatic or renal insufficiency\n* Administration of low-emetogenic chemotherapy\n* Mucositis (Oral Assessment Guide score: 15-24 points)",{"count":115,"type":22},72,[59],"Hematologic malignancies are the fifth most common type of cancer in the world. Patients with hematologic malignancies receive long-term and exhausting treatments such as chemotherapy, radiotherapy, hematopoietic stem cell transplantation and supportive therapies. Chemotherapy-induced nausea and vomiting has a significant impact on the daily lives of patients and causes physiological effects such as anorexia, malnutrition, weight loss, dehydration and electrolyte imbalance. It also has a negative impact on activities of daily living and psychological status, and may lead to poor adherence to chemotherapy regimens, refusal of chemotherapy or discontinuation of treatment. Oral mucosa is one of the areas most affected by the cytotoxic damage of chemotherapy. Disruption of the oral mucosa causes nausea, vomiting and feeding problems. Patients resort to non-drug approaches to manage these problems. It is important that these non-pharmacologic approaches are supported and controlled by reliable and evidence-based studies in order to prevent adverse effects on patient outcomes. In the literature, it has been determined that peppermint oil has antiemetic, antiseptic, anti-inflammatory, analgesic, antiseptic, antioxidant, antiviral, antifungal and spasmolytic effects, protects the integrity of the oral mucosa and has positive effects on nausea-vomiting and anorexia.\n\nIn this context, the aim of the study was to investigate the effect of a preventive oral care protocol with peppermint oil mouthwash on chemotherapy-induced nausea, vomiting and appetite in patients with hematologic malignancy.\n\nResearch Hypotheses H01: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the development of chemotherapy-induced nausea and vomiting.\n\nH02: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the severity of chemotherapy-induced nausea and vomiting.\n\nH03: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the development of chemotherapy-induced anorexia.\n\nH04: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the severity of chemotherapy-induced anorexia.\n\nMethods: The type of study is a single-blind randomized controlled experimental study. The research will be conducted between September 10, 2025, and April 10, 2026, with patients admitted to the hematology clinic of a university hospital for chemotherapy treatment. The study will be conducted with a total of 72 people who will be randomly assigned to the intervention (n=36) and control groups (n=36) by stratified and block randomization method. Patients who are 18 years of age or older, have hematologic malignancy, with a history of at least one chemotherapy cycle, and scheduled to receive chemotherapy with high or moderate emetogenic risk agents, do not have oral mucositis before chemotherapy, do not have metastasis, are literate and volunteer to participate in the study will be included in the study. Research data will be collected using the \"Patient Introduction Form\", \"Rhodes Nausea-Vomiting and Retching Index\", \"Oral Assessment Guide\", \"Appetite Assessment Chart \\[(Visual Analog Scale (VAS)\\]\", \"Peppermint Oil Protective Oral Care Protocol\", \"Food Intake Record Form\", \"Allergic Reaction Monitoring Form\" and \"Patient Monitoring Form and Antiemetic Record Chart\". In addition to the routine protective oral care (saline solution mouthwash and\u002For sodium bicarbonate mouthwash) in the clinic, \"Peppermint Oil Protective Oral Care Protocol\" will be applied to the intervention group for 6 days from the start of chemotherapy treatment. Patients will receive mouthwash prepared with 1 ml of peppermint oil and 50 ml of prepared drinking water 3 times a day. Patients in the intervention group will be monitored for 6 days by evaluating oral assessment, development of oral mucositis, appetite follow-up and compliance with mouthwash. The development of allergy due to the use of peppermint oil in each mouthwash application will be evaluated. The control group will not receive any oral care intervention by the researcher and will receive routine preventive oral care in the clinic. In the evaluation of the data, descriptive statistics, Chi-square \u002F Fisher's Exact test will be used for the relationship between categorical variables, Mann Whitney U test, Wilcoxon test, Kruskal-Wallis H test will be used for the relationship between continuous variables in groups that do not show normal distribution; one-way analysis of variance \u002F repeated measures analysis of variance, t test for dependent and independent groups will be used in groups with normal distribution. Correlation analysis and regression analysis will be used to examine the relationship between variables.",[119,120,121,28],"Hematologic Neoplasms","Nausea","Vomiting",[119,120,121,28,123,124],"Prevention Mouthrinse","peppermint oil","2025-09-15",{"date":127,"type":35},"2025-09-17",{"date":129,"type":22},"2025-09-10",{"date":131,"type":22},"2026-06-10",{"name":133,"class":42},"Şule Güzle",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":57,"phases":143,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100555831","phase-3-olanzapine-for-cancer-related-anorexia-cachexia-syndrome-100555831","NCT06517199","Olanzapine for Cancer Related Anorexia-cachexia Syndrome","Randomized Placebo-controlled Study of Olanzapine for Cancer Related Anorexia-cachexia Syndrome","Inclusion Criteria:\n\n* pathologically or cytologically metastatic or locally advanced cancer\n* anorexia and \\>=5% weight loss during the past 6 months or anorexia with numerical scale of anorexia \\>=5\n* ECOG performance status 0-3\n* able to complete questionaire and able to swallow pills\n\nExclusion Criteria:\n\n* receiving chemotherapy or anti-cancer systemic therapy\n* life expectancy longer than 1 month\n* received radiotherapy at head\u002Fneck or thoracic or upper abdomen in the past 2 weeks\n* surgery within 4 weeks\n* pregnancy\n* serum bilirubin \\> 2 mg\u002Fdl or serum Cr \\> 2 mg\u002Fdl\n* current use of olanzapine or other antipsychotic drug\n* known cardiac arrhythmia, uncontrolled brain metastasis, history of seizure or acute coronary event in the past 6 months",{"count":142,"type":22},138,[144],"PHASE3","Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.",[28,97],[148,149],"cancer anorexia","olanzapine","2024-07-18",{"date":152,"type":35},"2024-07-24",{"date":154,"type":35},"2024-01-22",{"date":156,"type":22},"2026-01-21",{"name":158,"class":42},"Mahidol University",2,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":43},"100527308","insights-into-participating-in-clinical-studies-for-anorexia-100527308","NCT06146075","Insights Into Participating in Clinical Studies for Anorexia","Assessing Engagement Patterns and Participation Trends in Individuals Joining Anorexia Clinical Trials","Inclusion Criteria:\n\n* Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed\n* Diagnosis of anorexia\n* No prior treatment for anorexia\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Any serious and\u002For unstable pre-existing medical disorders\n* Patients receiving any other investigational agents",{"count":168,"type":22},500,"Clinical trials centered on anorexia serve a pivotal function in assessing the safety and effectiveness of emerging treatments for this condition.\n\nThe primary aim revolves around meticulously scrutinizing both trial completion rates and instances of voluntary withdrawal within specific patient cohort.",[28],[172],"anorexia","2023-11-17",{"date":175,"type":35},"2023-11-24",{"date":177,"type":22},"2024-12",{"date":179,"type":22},"2026-12",{"name":181,"class":182},"Power Life Sciences Inc.","INDUSTRY"]